Discontinued — last reported Q4 '25
MRSH Acquisitions decreased by 90.4% to $41.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 127.8%, from $18.00M to $41.00M. Over 2 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -12.9% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $350.00M | $34.00M | $475.00M | $24.00M | $244.00M | $244.00M | $244.00M | $244.00M | $301.00M | $343.00M | $18.00M | $44.00M | $162.00M | $428.00M | $41.00M |
| QoQ Change | — | -90.3% | >999% | -94.9% | +916.7% | +0.0% | +0.0% | +0.0% | +23.4% | +14.0% | -94.8% | +144.4% | +268.2% | +164.2% | -90.4% |
| YoY Change | — | — | — | — | +916.7% | — | — | — | +23.4% | +40.6% | -94.0% | -87.2% | — | — | +127.8% |